Excellent Outcomes with Strut-Based Brachytherapy
ALISO VIEJO, CA – Cianna Medical, Inc., a women’s health company, today announced results of two new studies showing excellent longer-term outcomes with the SAVI® breast brachytherapy applicator, including low recurrence rates, few toxicities, excellent cosmetic outcomes and high rates of survival. A third study demonstrated SAVI’s ability to precisely deliver radiation while avoiding critical structures. SAVI is a strut-based applicator that delivers accelerated partial breast irradiation (APBI), a 5-day course of targeted radiation for early-stage breast cancer.
Data came from the SAVI Collaborative Research Group (SCRG), which studies the long-term outcomes of women treated with ABPI with SAVI and will be presented as posters at the 55th annual meeting of the American Society for Radiation Oncology (ASTRO), September 22-25, 2013, in Atlanta.
“APBI is an accepted treatment for certain women with early-stage breast cancer, with multiple Phase II and III clinical trials demonstrating its efficacy and safety,” said Robert Kuske, MD, co-principal investigator of the SCRG and a radiation oncologist at Arizona Breast Cancer Specialists, Phoenix, Ariz. “This new data further validates strut-based brachytherapy as a safe and effective method for delivering partial breast radiation, which means more women will have access to a treatment that delivers highly targeted radiation with much greater convenience.”
The first study detailed outcomes with the most mature follow-up of patients treated with strut-based APBI. The multi-institutional study examined 101 patients with a median follow-up of 4.5 years, reporting very low toxicity rates (< 3%) and excellent local control (2%). Overall and cause-specific actuarial survival rates were 100%. Continue>